Processa Pharmaceuticals Inc (NASDAQ:PCSA) shares traded 14.31% higher at $0.24 on Wall Street last session.
PCSA stock price is now -6.25% away from the 50-day moving average and -64.53% away from the 200-day moving average. The market capitalization of the company currently stands at $6.36M.
With the price target of $8, H.C. Wainwright recently initiated with Buy rating for Processa Pharmaceuticals Inc (NASDAQ: PCSA).
In other news, Yorke Justin W, Director bought 12,400 shares of the company’s stock on Jan 27 ’25. The stock was bought for $9,889 at an average price of $0.80. Upon completion of the transaction, the Director now directly owns 12,400 shares in the company, valued at $2976.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 27 ’25, Chief Executive Officer Ng George K bought 87,200 shares of the business’s stock. A total of $69,542 was incurred on buying the stock at an average price of $0.80. This leaves the insider owning 87,200 shares of the company worth $20928.0. A total of 13.24% of the company’s stock is owned by insiders.
During the past 12 months, Processa Pharmaceuticals Inc has had a low of $0.15 and a high of $3.10. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 2.93, and a quick ratio of 2.93. The fifty day moving average price for PCSA is $0.25904 and a two-hundred day moving average price translates $0.68456 for the stock.
The latest earnings results from Processa Pharmaceuticals Inc (NASDAQ: PCSA) was released for 2025-03-31.
